SCOPE 2—Coverage of TCT Connect 2020 | SCAI

SCOPE 2 randomized 796 patients, age 75 years or older (mean 83.2 years), with symptomatic severe aortic stenosis, to one of two self-expanding TAVR devices, CoreValve Evolut (Medtronic) or ACURATE neo (Boston Scientific). The primary endpoint of death or stroke at 1 year occurred in 13.9 percent of patients receiving CoreValve and 15.8 percent of those treated with Acuate neo, failing to meet statistical noninferiority (P=0.0549). The ACURATE neo group also showed higher rates of moderate-to-severe aortic regurgitation (10.0% vs 3.0%; P=0.02) but lower rates of pacemaker requirement at 30 days (11.0% vs 18.0%; p = 0.0027). 

All Editors: David A. Cox, MD, MSCAI; Allison G. Dupont, MD, FSCAI; Kirk N. Garratt, MD, MSc. MSCAI; Cindy L. Grines, MD, MSCAI; Andrew J. Klein, MD, FSCAI; and Jordan Saferstein, MD, FSCAI. 

Integrated Search Topics